Abstract
Infliximab is effective as a third-line therapeutic for severe sarcoidosis; however, long-term efficacy is unknown. The aim of this study was to assess the relapse rate after discontinuation of infliximab in sarcoidosis patients and predict relapse by analysis of the activity marker soluble interleukin (IL)-2 receptor (sIL-2R) and maximum standardised uptake value (SUVmax) of18F-fluorodeoxyglucose positron emission tomography (FDG PET).
在这项回顾性队列研究中,使用Kaplan -Meier方法分析了复发的比例,并使用COX回归研究了预测因素。
47 sarcoidosis patients who started infliximab therapy were included in the risk analysis. Kaplan–Meier analysis revealed a median time to relapse of 11.1 months and showed that 25% of the cohort relapsed within 4 months. Both mediastinal SUVmax≥6.0 on FDG PET (hazard ratio 3.77, p<0.001) and serum sIL-2R ≥4000 pg·mL−1(hazard ratio 2.24, p=0.033) at start of therapy predicted relapse. In multivariate analysis, a mediastinal SUVmax≥6.0 at initiation of therapy was an independent predictor of relapse (hazard ratio 4.33, p<0.001).
The majority of patients that discontinued infliximab therapy relapsed. High serum sIL-2R and high SUVmaxon FDG PET at initiation of therapy were significant predictors of relapse. These results suggest close monitoring of patients in this category when they discontinue infliximab treatment.
Abstract
Two significant predictors of relapse after discontinuation of infliximab therapy for severe sarcoidosishttp://ow.ly/qXWuq
脚注
有关社论评论,请参见第337页.
Conflict of interest: None declared.
- 已收到March 27, 2013.
- AcceptedAugust 2, 2013.
- ©ERS 2014